Table 3.
A joint pathway analysis of NER & BER polymorphisms in esophageal adenocarcinoma risk using an additive genetic model
| # at-risk alleles | Case (%) | Control (%) | Crude odds ratio (95% CI) | Adjusted odds ratioa (95% CI) |
|---|---|---|---|---|
| NER | ||||
| 0 | 49 (16) | 95 (21) | 1 | 1 |
| 1–2 | 94 (30) | 148 (33) | 1.23 (0.8–1.9) | 1.24 (0.8–1.9) |
| 3–4 | 97 (31) | 132 (29) | 1.43 (0.9–2.2) | 1.53 (1.0–2.4) |
| 5–6 | 50 (16) | 61 (13) | 1.59 (1.0–2.6) | 1.76 (1.0–3.0) |
| 7–8 | 20 (6) | 16 (4) | 2.42 (1.2–5.1) | 2.39 (1.1–5.2) |
| BER | ||||
| 0 | 16 (5) | 30 (6) | 1 | 1 |
| 1 | 95 (31) | 135 (28) | 1.32 (0.7–2.6) | 1.58 (0.8–3.2) |
| 2 | 82 (27) | 180 (37) | 1.03 (0.5–2.0) | 1.19 (0.6–2.4) |
| 3 | 78 (25) | 81 (17) | 1.81 (0.9–3.6) | 2.07 (1.0–4.2) |
| 4–6 | 37 (12) | 55 (11) | 1.26 (0.6–2.6) | 1.48 (0.7–3.2) |
a
Adjusted for age, sex, smoking status, and adult BMI